The Health Services of Synchrony As was previously reported, Trilogy Health Services, headquartered in Louisville, is the parent company of Synchrony Health Services. Trilogy Health Services is Louisville’s fourth-largest private company in terms of revenue, and it is responsible for the merger that created Synchrony Health Services by combining PCA Pharmacy and Paragon Rehabilitation.
Is PCA Skin owned by Colgate?
The Colgate-Palmolive Company owns the skincare brand PCA Skin (NYSE:CL). They simultaneously bought PCA Skin and EltaMD in an effort to broaden their presence in the personal care industry. Where exactly did PCA Skin come from?
Is PCA Skin a good brand?
An Overview of PCA Skin An aesthetician and a dermatologist established PCA Skin in 1990. PCA Skin is a skincare company. Its objective may be broken down into three distinct categories: product innovation, educational leadership, and unrivaled service for customers.
Their claim to fame is the development of Jessner’s peel, which is still used widely today; more than one million PCA Skin peels are carried out each year throughout the world. PCA Skin, which was just recently purchased by the Colgate-Palmolive Company, places a significant emphasis not only on research and development but also on quality assurances.
Customers can see this emphasis on research and development exhibited in their listing of authorized and unauthorized retailers of PCA Skin products. PCA Skin also employs an in-house PhD chemist who works tirelessly to develop and design innovative formulae for clinical-grade skin care products.
How big is the PCAS company?
PCAS is the chosen industrial partner for market-leading big worldwide groups due to the company’s broad international reach and the fact that it allocates close to 7% of its net revenues to research and development. The firm also has a subsidiary in the biotechnology industry called Protéus, which has a very high potential for growth, and it provides an expanding selection of proprietary goods and solutions in cutting-edge markets.
Why invest in PCAS?
PCAS is the chosen industrial partner for market-leading big worldwide groups due to the company’s broad international reach and the fact that it allocates close to 7% of its net revenues to research and development. The firm also has a subsidiary in the biotechnology industry called Protéus, which has a very high potential for growth, and it provides an expanding selection of proprietary goods and solutions in cutting-edge markets.